LCTX Lineage Cell Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: LCTX

Price (delayed)

$1.01

Market cap

$176.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.13

Enterprise value

$148.34M

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house ...

Highlights
LCTX's EPS has soared by 55% year-on-year
The company's net income has surged by 53% YoY but it fell by 4.7% QoQ
The debt has grown by 10% YoY but it has contracted by 10% from the previous quarter
The gross profit has contracted by 37% YoY and by 17% from the previous quarter
The revenue has contracted by 37% YoY and by 17% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://lineagecell.com
Peers: OMGA

Key stats

What are the main financial stats of LCTX
Market
Shares outstanding
174.99M
Market cap
$176.74M
Enterprise value
$148.34M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.59
Price to sales (P/S)
20.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.91
Earnings
Revenue
$8.77M
EBIT
-$24.43M
EBITDA
-$23.74M
Free cash flow
-$31.42M
Per share
EPS
-$0.13
Free cash flow per share
-$0.18
Book value per share
$0.39
Revenue per share
$0.05
TBVPS
$0.28
Balance sheet
Total assets
$106.15M
Total liabilities
$39.49M
Debt
$3.08M
Equity
$68.12M
Working capital
$27.6M
Liquidity
Debt to equity
0.05
Current ratio
2.74
Quick ratio
2.63
Net debt/EBITDA
1.2
Margins
EBITDA margin
-270.7%
Gross margin
94.1%
Net margin
-262.9%
Operating margin
-285.1%
Efficiency
Return on assets
-20.3%
Return on equity
-32.4%
Return on invested capital
-123.5%
Return on capital employed
-27.1%
Return on sales
-278.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LCTX stock price

How has the Lineage Cell Therapeutics stock price performed over time
Intraday
6.32%
1 week
1%
1 month
-10.62%
1 year
-31.29%
YTD
-13.68%
QTD
-14.41%

Financial performance

How have Lineage Cell Therapeutics's revenue and profit performed over time
Revenue
$8.77M
Gross profit
$8.26M
Operating income
-$25.01M
Net income
-$23.07M
Gross margin
94.1%
Net margin
-262.9%
The company's net income has surged by 53% YoY but it fell by 4.7% QoQ
The operating income has increased by 43% year-on-year but it has declined by 6% since the previous quarter
The gross profit has contracted by 37% YoY and by 17% from the previous quarter
The revenue has contracted by 37% YoY and by 17% from the previous quarter

Growth

What is Lineage Cell Therapeutics's growth rate over time

Valuation

What is Lineage Cell Therapeutics stock price valuation
P/E
N/A
P/B
2.59
P/S
20.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.91
LCTX's EPS has soared by 55% year-on-year
LCTX's P/B is 19% below its last 4 quarters average of 3.2 but 3.6% above its 5-year quarterly average of 2.5
LCTX's equity is down by 14% YoY and by 6% QoQ
LCTX's price to sales (P/S) is 69% less than its 5-year quarterly average of 65.2
The revenue has contracted by 37% YoY and by 17% from the previous quarter

Efficiency

How efficient is Lineage Cell Therapeutics business performance
Lineage Cell Therapeutics's ROIC has soared by 88% YoY but it has decreased by 40% from the previous quarter
LCTX's return on equity is up by 44% year-on-year but it is down by 9% since the previous quarter
Lineage Cell Therapeutics's ROA has increased by 39% YoY but it has decreased by 10% from the previous quarter
LCTX's ROS is down by 28% since the previous quarter but it is up by 18% year-on-year

Dividends

What is LCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LCTX.

Financial health

How did Lineage Cell Therapeutics financials performed over time
LCTX's total assets is 169% greater than its total liabilities
LCTX's total liabilities is down by 26% year-on-year and by 2.3% since the previous quarter
LCTX's total assets is down by 19% year-on-year and by 5% since the previous quarter
The debt is 95% less than the equity
The debt to equity has grown by 25% YoY
LCTX's equity is down by 14% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.